$ALKS

Alkermes' ALKS 7290, an orexin 2 receptor agonist, showed significant improvement in adult ADHD symptoms in a Phase 1B study. The drug reduced ADHD symptoms by 14-19 points and severity scores by 1-2 points. It was well-tolerated with mild side effects. Alkermes plans further trials, with results expected in 2027.

Alkermes (ALKS) will present new data on Alixorexton and LUMRYZ at Sleep Europe 2026. The company will share findings from the Vibrance-1 phase 2 study of Alixorexton in narcolepsy and the REVITALYZ phase 3 study of LUMRYZ in idiopathic hypersomnia. Alkermes acquired LUMRYZ as part of its purchase of Avadel Pharmaceuticals.

Analysts from Guggenheim and J.P. Morgan reiterated Buy ratings on AbbVie (ABBV) with price targets of $288 and $285, respectively. Meanwhile, Bank of America Securities maintained a Sell rating on Alkermes (ALKS) with a $38 price target. ABBV closed at $272.42, ALKS at $40.11.

Stifel reiterated a Buy rating and $63 price target for Alkermes (ALKS), citing confidence in its pipeline and upcoming clinical trial readouts. The stock has gained 49% year-to-date. Analysts highlight positive Phase Ib trial results for ALKS 7290 in ADHD and strong enrollment in Brilliance phase 3 trials. Other analysts have mixed ratings and targets, ranging from $50 to $65.

Alkermes (ALKS) EVP and Chief Legal Officer David Gaffin sold 2,034 shares on 2026-10-02, per SEC filing. He now owns 221,388 shares. Over the past year, he sold 18,306 shares with no purchases. The company had 29 insider sells and 0 buys in the same period. ALKS trades at $41.03, with a P/E of 108.44, above industry median and historical levels. GuruFocus values it at $32.72, deeming it 'Modestly Overvalued'.

Alkermes officer David Gaffin proposed selling 2,034 shares worth $83.5K, with a planned sale date of October 2, 2026. He previously sold 2,034 shares on four occasions between June and September 2026, with proceeds ranging from $87.6K to $109.9K. The company's outstanding shares total 167.8M.

Alkermes presented data showing Lybalvi (olanzapine/samidorphan) reduced hospital and emergency visits in schizophrenia and bipolar I patients with alcohol use disorder, according to Hemangi Panchmatia. Long-term data showed stable metabolic parameters and better adherence. Separately, aripiprazole lauroxil demonstrated symptom reductions and a favorable adverse event profile, per Dr. McGrory.

Alkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.

Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.

Alkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.